-
Mashup Score: 44Could CAR T-Cell Therapy Be a Cure for Some Cancers? - 4 month(s) ago
Discover the revolutionary potential of CAR T-cell therapy, the intricate process of modifying a patient’s own immune cells to target and eliminate cancer cells.
Source: www.mskcc.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 14
An FDA investigation into links between CAR-T immunotherapy and new cancers comes as a surprise to many scientists in the field.
Source: www.statnews.comCategories: General Medicine News, Expert PicksTweet-
FDA investigating whether #CART, a treatment for cancer, can also cause lymphoma https://t.co/XQ6GjwLPQG via @statnews
-
-
Mashup Score: 14
An FDA investigation into links between CAR-T immunotherapy and new cancers comes as a surprise to many scientists in the field.
Source: www.statnews.comCategories: General Medicine News, Expert PicksTweet-
FDA investigating whether #CART, a treatment for cancer, can also cause lymphoma https://t.co/XQ6GjwLPQG via @statnews
-
-
Mashup Score: 14
An FDA investigation into links between CAR-T immunotherapy and new cancers comes as a surprise to many scientists in the field.
Source: www.statnews.comCategories: General Medicine News, Expert PicksTweet-
FDA investigating whether #CART, a treatment for cancer, can also cause lymphoma https://t.co/XQ6GjwLPQG via @statnews
-
-
Mashup Score: 14
An FDA investigation into links between CAR-T immunotherapy and new cancers comes as a surprise to many scientists in the field.
Source: www.statnews.comCategories: General Medicine News, Expert PicksTweet-
FDA investigating whether #CART, a treatment for cancer, can also cause lymphoma https://t.co/XQ6GjwLPQG via @statnews
-
-
Mashup Score: 13Miguel Ángel Perales, oncólogo: “Lo que estamos haciendo hoy con la terapia celular CAR-T contra el cáncer parece ciencia ficción” - 6 month(s) ago
El científico del Memorial Sloan Kettering de Nueva York asegura que esta técnica ha significado “un cambio total” del pronóstico de muchos enfermos
Source: elpais.comCategories: General Medicine News, Hematologists1Tweet-
Miguel Ángel Perales, oncólogo: “Lo de la terapia celular contra el cáncer parece ciencia ficción” - @DrMiguelPerales terapia #CART @sehh @SEHHJoven @GETH_info @_pethema @Red_TerCel https://t.co/CONJM39z3o
-
-
Mashup Score: 4Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma - 7 month(s) ago
The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a c…
Source: www.tandfonline.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Full article: Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma https://t.co/8dJRPL9B8S
-
For those of you who love an indirect comparison... Post cov. BTKi management in #MCL CAR-T vs non-CART approaches from the SCHOLAR-R: overall survival analysis #lymsm #MCL #CART https://t.co/8dJRPL9B8S https://t.co/RvJFvoZVnE
-
-
Mashup Score: 0Probiotic-guided CAR-T cells for solid tumor targeting - 7 month(s) ago
Engineered probiotics produce synthetic targets to facilitate immunotherapy of solid tumors by CAR T cells.
Source: www.science.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Probiotic-guided CAR-T cells for solid tumor targeting | Science https://t.co/BMxIV9gLRu #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy
-
-
Mashup Score: 1A Novel Allogeneic Rituximab-Conjugated Gamma Delta T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Lymphoma - 7 month(s) ago
Chimeric antigen receptor T cell (CAR-T) therapy has been applied in the treatment of B-cell lymphoma; however, CAR-T manufacturing requires virus- or non-virus-based genetic modification, which causes high manufacturing costs and potential safety concerns. Antibody–cell conjugation (ACC) technology, which originated from bio-orthogonal click chemistry, provides an efficient approach for arming immune cells with cancer-targeting antibodies without genetic modification. Here, we applied ACC technology in Vγ9Vδ2 T (γδ2 T) cells to generate a novel off-the-shelf CD20-targeting cell therapy ACE1831 (rituximab-conjugated γδ2 T cells) against relapsed/refractory B-cell lymphoma. ACE1831 exhibited superior cytotoxicity against B-cell lymphoma cells and rituximab-resistant cells compared to γδ2 T cells without rituximab conjugation. The in vivo xenograft study demonstrated that ACE1831 treatment strongly suppressed the aggressive proliferation of B-cell lymphoma and prolonged the survival of t
Source: www.mdpi.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A Novel Allogeneic Rituximab-Conjugated Gamma Delta T Cell Rx for the Rx of Relapsed/Refractory B-Cell Lymphoma https://t.co/iHVarmT8Rs #mdpicancers via @Cancers_MDPI #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy
-
-
Mashup Score: 0
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of malignancies, especially hematological tumors, but toxicities have tempered its success. The main impediments to the development of CAR-T cell therapies are the following: cytokine release syndrome (CRS), immune-effector-cell-associated neurotoxicity syndrome (ICANS), tumor lysis syndrome (TLS), and on-target/off-tumor toxicity (OTOT). This review summarizes these side effects’ underlying mechanisms and manifestations over time. It provides potential prevention and treatment according to the consensus grading, stressing the significance of establishing strategies that anticipate, reduce, and navigate the beginning of these side effects. It is essential to fully comprehend the mechanisms underlying these toxicities to create efficient treatment and preventive approaches.
Source: www.mdpi.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies https://t.co/5Rsa1rvzzy #mdpijcm via @JCM_MDPI #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy
-
In this episode of the Cancer Straight Talk Podcast from MSK, host @DianeReidyLagun sits down w/Dr. Michel Sadelain & Dr. Jae Park to discuss the intricate process of engineering a patient's immune cells to selectively destroy cancer cells. Listen: https://t.co/nigvceXEwQ #CART https://t.co/mb9A6SxYn0